Quarterly report pursuant to sections 13 or 15(d)

6. Stock options and warrants

v2.3.0.11
6. Stock options and warrants
3 Months Ended
Mar. 31, 2012
Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity [Table Text Block]

6.  Stock options and warrants


The Company periodically issues stock options and warrants to employees and non-employees in capital raising transactions, for services and for financing costs.  Stock-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite service period.  Options vest and expire according to terms established at the grant date.


Options


The Company currently issues stock options to employees, directors and consultants under the 2004 Stock Option Plan (the Plan). The Company could issue options under the Plan to acquire up to 5,000,000 shares of common stock. In February 2006, the board approved an amendment to the Plan (approved by the Shareholders in May 2006), increasing the authorized shares by 2,000,000 shares to 7,000,000 shares. At March 31, 2012, 2,750,442 were available to be granted under the Plan. Prior to 2004, the Company granted 3,250,000 options outside the Plan to officers of the Company.


On February 1, 2012, the Company issued 4,000,000 options to its Chief Financial Officer. The options have an exercise price of $0.25 per share, vest over a four year period, and expire ten years from date of grant. Twelve and a half percent vested immediately, twelve and a half percent will vest on the first anniversary date, and twenty-five percent will vest on the following three anniversary dates.


Employee options vest according to the terms of the specific grant and expire from 5 to 10 years from date of grant. Non-employee option grants to date are vested upon issuance. The weighted-average, remaining contractual life of employee options outstanding at March 31, 2012 was 8.5 years. Stock option activity for the period January 1, 2012 to March 31, 2012, was as follows:


Options   Shares    

Weighted-

Average

Exercise

Price

   

Weighted-

Average

Remaining

Contractual

Term

   

Aggregate

Intrinsic

Value

 
Outstanding at January 1, 2012     24,067,892     $ 0.30              
Granted     4,000,000       0.25              
Exercised     (18,334 )     0.27              
Forfeited or expired                        
Outstanding at March 31, 2012     28,049,558     $ 0.30       8.5     $ 7,738,607  
Vested and exercisable at March 31, 2012     10,469,558     $ 0.37       7.9     $ 2,464,607  

The weighted average exercise prices, remaining contractual lives for options granted, exercisable, and expected to vest under the Plan as of March 31, 2012 were as follows:


  Outstanding Options   Exercisable Options
Option
Exercise Price Per Share
  Shares   Life
(Years)
  Weighted
Average
Exercise
Price
  Shares   Weighted Average Exercise
Price
  $ 0.21 - $ 0.99       27,722,012       8.6     $ .28       10,142,012     $ 0.34  
  $ 1.00 - $ 1.99       327,546       3.1       1.25       327,546       1.25  
          28,049,558       8.5     $ 0.30       10,469,558     $ 0.37  

During the three months ended March 31, 2012, the Company amortized $517,761 of compensation cost based on the vesting of the options. Future unamortized compensation expense on the outstanding options at March 31, 2012 is $6,270,721.


Black-Scholes-Merton value of options


During the three months ended March 31, 2012 and 2011, the Company valued options for pro-forma purposes at the grant date using the Black-Scholes-Merton pricing model with the following average assumptions:


    March 31,
    2012   2011
                 
Expected life (years)     10.0       10.0  
Risk free interest rate     1.27%       1.95%  
Volatility      124.90%       134.82%  
Expected dividend yield     0.00%       0.00%  

Warrants


During the period ended March 31, 2012, the Company granted warrants to consultants to purchase 600,000 shares of its common stock.  The warrants have an average exercise price of $0.26/share, vesting immediately and will expire in two to three years from grant date.  Total fair value of the warrant amounted to $123,734 using the Black-Scholes Merton valuation model with the following average assumptions: risk-free interest rate of 0.23% to 0.37%; dividend yield of 0%; volatility of 112%; and an expected life of two to three years.  During the period ended March 31, 2012, the Company recognized amortization expense of $123,734 based upon vesting of the warrants.


During the period ended March 31, 2012, the Company granted issued 5,959,216 warrants to acquire shares of its common stock in connection of its issuance of convertible notes.  The warrant is exercisable at $0.25/share, fully vested, and will expire in two years for date of grant (See note 4).


The following table summarizes certain information about the Company’s stock purchase warrants from January 1, 2012 to March 31, 2012:


Warrants   Shares   Weighted-
Average
Exercise
Price
  Weighted-
Average
Remaining
Contractual
Term
  Aggregate
Intrinsic
Value
Outstanding at January 1, 2012     49,106,280     $ 0.32                  
Granted     6,559,216       0.30                  
Exercised     (867,250 )     0.40                  
Forfeited or expired     (1,834,907 )     0.48                  
Outstanding at March 31, 2012     52,963,339     $ 0.31       1.7     $ 13,224,852  
Vested and exercisable at March 31, 2012     51,205,006     $ 0.31       1.7     $ 12,785,269  

  Outstanding Warrants   Exercisable Warrants
Warrant
Exercise Price Per Share
  Shares   Life
(Years)
  Weighted
Average
Exercise
Price
  Shares   Weighted Average Exercise
Price
  $ 0.25 - $ 0.99       51,963,339       1.8     $ .30       50,205,006     $ 0.30  
  $ 1.00 - $ 1.99       1,000,000       1.2       1.00       1,000,000       1.00  
          52,963,339       1.7     $ 0.31       51,205,006     $ 0.31  

During the three months ended March 31, 2012, The Company amortized $240,422 of the compensation based on the vesting of these warrants. Future unamortized compensation expense on the outstanding warrants at March 31, 2012 is $369,512.